Current adoptive immunotherapy in non-small cell lung cancer and potential influence of therapy outcome

Cancer Investigation

Volumn 31, Issue 3, 2013, Pages 197-205

  Zheng, Ya Wen ^a   Li, Run Mei ^a   Zhang, Xin Wei ^a   Ren, Xiu Bao ^a  

^a TIANJIN MEDICAL UNIVERSITY   (China)

Author keywords

Adoptive immunotherapy; Clinical study; Influence factor; Non small cell lung cancer

Indexed keywords

ANTINEOPLASTIC AGENT; CISPLATIN; CYCLOPHOSPHAMIDE; GAMMA INTERFERON; INTERLEUKIN 1ALPHA; INTERLEUKIN 2; RECOMBINANT INTERLEUKIN 2;

ADOPTIVE IMMUNOTHERAPY; ADVERSE OUTCOME; ARTICLE; CANCER CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER RADIOTHERAPY; CANCER SURVIVAL; CELL THERAPY; CYTOKINE INDUCED KILLER CELL; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; FEVER; GAMMA DELTA T LYMPHOCYTE; HUMAN; INFLUENZA; LUNG NON SMALL CELL CANCER; LYMPHOKINE ACTIVATED KILLER CELL; NONHUMAN; PATIENT SAFETY; PRIORITY JOURNAL; T LYMPHOCYTE; TREATMENT OUTCOME; TUMOR ASSOCIATED LEUKOCYTE;

CARCINOMA, NON-SMALL-CELL LUNG; HUMANS; IMMUNOTHERAPY, ADOPTIVE; LUNG NEOPLASMS; TREATMENT OUTCOME;

EID: 84875013121     PISSN: 07357907     EISSN: 15324192     Source Type: Journal    
DOI: 10.3109/07357907.2013.775294     Document Type: Article

References (98)

1. Tucker ZC, Laguna BA, Moon E, et al. Adjuvant immunotherapy for non-small cell lung cancer. Cancer Treat Rev 2012.
2. Saijo N. Problems involved in the clinical trials for non-small cell lung carcinoma. Cancer Treat Rev 2012;38:194-202.
3. Jemal A, Bray F, Center MM, et al. Global cancer statistics. CA Cancer J Clin 2011;61:69-90.
4. Mellman I, Coukos G, Dranoff G. Cancer immunotherapy comes of age. Nature 2011;480:480-489.
5. DouganM, Dranoff G. Immune therapy for cancer. Annu Rev Immunol 2009;27:83-117.
6. LumLG. T cell-based immunotherapy for cancer: a virtual reality? CA Cancer J Clin 1999;49(2):74-100, 65.
7. Decoster L, Wauters I, Vansteenkiste JF. Vaccination therapy for non-small-cell lung cancer: review of agents in phase III development. Ann Oncol 2011.
8. Custodio A, Mendez M, Provencio M. Targeted therapies for advanced non-small-cell lung cancer: current status and future implications. Cancer Treat Rev 2012;38:36-53.
9. Yang K, Wang YJ, Chen XR, et al. Effectiveness and safety of bevacizumab for unresectable non-small-cell lung cancer: a metaanalysis. Clin Drug Investig 2010;30:229-241.
10. Tomasini P, Khobta N, Greillier L, et al. Ipilimumab: its potential in non-small cell lung cancer. Ther AdvMed Oncol 2012;4:43-50.
11. Simmons O,Magee M, Nemunaitis J. Current vaccine updates for lung cancer. Expert Rev Vaccines 2010;9:323-335.
12. Wang J, Zou ZH, Xia HL, et al. Strengths and weaknesses of immunotherapy for advanced non-small-cell lung cancer: a meta-analysis of 12 randomized controlled trials. PLoS One 2012;7:e32695.
13. Ballen K, Stewart FM. Adoptive immunotherapy. Curr Opin Oncol 1997;9:579-583.
14. Dasanu CA, Sethi N, AhmedN. Immune alterations and emerging immunotherapeutic approaches in lung cancer. Expert Opin Biol Ther 2012.
15. Barrett J, Bollard CM. T-cell therapy for cancer. Immunotherapy 2012;4:347-350.
16. Vera JF, Brenner LJ, Gerdemann U, et al. Accelerated production of antigen-specific T cells for preclinical and clinical applications using gas-permeable rapid expansion cultureware (G-Rex). J Immunother 2010;33:305-315.
17. Sinkovics JG, Horvath JC. Human natural killer cells: a comprehensive review. Int J Oncol 2005;27:5-47.
18. Wu R, Forget MA, Chacon J, et al. Adoptive T-cell therapy using autologous tumor-infiltrating lymphocytes for metastatic melanoma: current status and future outlook. Cancer J 2012;18:160-175.
19. Nguyen LT, Yen PH, Nie J, et al. Expansion and characterization of humanmelanoma tumor-infiltrating lymphocytes (TILs). PLoS One 2010;5:e13940.
20. Hontscha C, Borck Y, Zhou H, et al. Clinical trials on CIK cells: first report of the international registry on CIK cells (IRCC). J Cancer Res Clin Oncol 2011;137:305-310.
21. Mesiano G, Todorovic M, Gammaitoni L, et al. Cytokine-induced killer (CIK) cells as feasible and effective adoptive immunotherapy for the treatment of solid tumors. Expert Opin BiolTher 2012.
22. Linn YC, Hui KM. Cytokine-induced NK-like T cells: from bench to bedside. J Biomed Biotechnol 2010;2010:435745. doi:10.1155/2010/435745.
23. HuiKM. CIK cells - current status, clinical perspectives and future prospects - the good news. Expert Opin BiolTher 2012.
24. Ma Y, Zhang Z, Tang L, et al. Cytokine-induced killer cells in the treatment of patients with solid carcinomas: a systematic review and pooled analysis. Cytotherapy 2012;14:483-493.
25. Zhang J, Zhu L, Wei J, et al. The effects of cytokine-induced killer cells for the treatment of patients with solid tumors: a clinical retrospective study. J Cancer Res Clin Oncol 2012;138:1057- 1062.
26. Hayday AC. Gammadelta T cells and the lymphoid stresssurveillance response. Immunity 2009;31:184-196.
27. Yoshida Y, Nakajima J, Wada H, et al. Gammadelta T-cell immunotherapy for lung cancer. Surg Today 2011;41:606-611.
28. Liu Z, Eltoum IE, Guo B, et al. Protective immunosurveillance and therapeutic antitumor activity of gammadelta T cells demonstrated in a mouse model of prostate cancer. J Immunol 2008;180:6044-6053.
29. Riley CL, Mathieu MG, Clark RE, et al. Tumour antigen-targeted immunotherapy for chronic myeloid leukaemia: is it still viable? Cancer Immunol Immunother 2009;58:1489-1499.
30. Zhukova OS, Gerasimova GK, Shubina I, et al. Combined effect of cisplatin and lymphokine-activated killer cells on A549 cells of non-small cell lung cancer. Bull Exp Biol Med 2007;144:231-234.
31. Liu C, Betancourt A, Cohen DA, et al. Granzyme B-mRNA expression by equine lymphokine activated killer (LAK) cells is associated with the induction of apoptosis in target cells. Vet Immunol Immunopathol 2011;143:108-115.
32. Kimura H, Yamaguchi Y. Adjuvant immunotherapy with interleukin 2 and lymphokine-activated killer cells after noncurative resection of primary lung cancer. Lung Cancer 1995;13:31-44.
33. Kimura H, Yamaguchi Y. A phase III randomized study of interleukin-2 lymphokine-activated killer cell immunotherapy combined with chemotherapy or radiotherapy after curative or noncurative resection of primary lung carcinoma. Cancer 1997;80:42-49.
34. Yano T, Sugio K, Yamazaki K, et al. Postoperative adjuvant adoptive immunotherapy with lymph node-LAK cells and IL-2 for pathologic stage I non-small cell lung cancer. Lung Cancer 1999;26:143-148.
35. Ebina T, Fujimiya Y. Cell transfer regimens in patients with highly advanced surgically unresectable non-small cell lung cancer: significantly improved overall survival in patients with lower levels of serum immunosuppressive acidic protein. Lung Cancer 2008;60:246-251.
36. Kilic A, Landreneau RJ, Luketich JD, et al. Density of tumorinfiltrating lymphocytes correlates with disease recurrence and survival in patients with large non-small-cell lung cancer tumors. J Surg Res 2011;167:207-210.
37. LiuH, Zhang T, Ye J, et al. Tumor-infiltrating lymphocytes predict response to chemotherapy in patients with advance non-small cell lung cancer. Cancer Immunol Immunother 2012;61:1849-1856.
38. Ratto GB, Zino P, Mirabelli S, et al. A randomized trial of adoptive immunotherapy with tumor-infiltrating lymphocytes and interleukin-2 versus standard therapy in the postoperative treatment of resected nonsmall cell lung carcinoma. Cancer 1996;78:244-251.
39. Amedei A, Niccolai E, Della BC, et al. Characterization of tumor antigen peptide-specific T cells isolated from the neoplastic tissue of patientswithgastric adenocarcinoma. Cancer Immunol Immunother 2009;58:1819-1830.
40. Dudley ME, Wunderlich JR, Yang JC, et al. Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma. J Clin Oncol 2005;23:2346-2357.
41. Radvanyi LG, Bernatchez C, Zhang M, et al. Specific lymphocyte subsets predict response to adoptive cell therapy using expanded autologous tumor-infiltrating lymphocytes in metastatic melanoma patients. Clin Cancer Res 2012.
42. Kim HM, Lim J, Park SK, et al. Antitumor activity of cytokineinduced killer cells against human lung cancer. Int Immunopharmacol 2007;7:1802-1807.
43. Li H, Wang C, Yu J, et al. Dendritic cell-activated cytokineinduced killer cells enhance the anti-tumor effect of chemotherapy on non-small cell lung cancer in patients after surgery. Cytotherapy 2009;11:1076-1083.
44. Li R,Wang C, Liu L, et al. Autologous cytokine-induced killer cell immunotherapy in lung cancer: a phase II clinical study. Cancer Immunol Immunother 2012.
45. Wu C, Jiang J, Shi L, et al. Prospective study of chemotherapy in combination with cytokine-induced killer cells in patients suffering from advanced non-small cell lung cancer. Anticancer Res 2008;28:3997-4002.
46. Iwai K, Soejima K, Kudoh S, et al. Extended survival observed in adoptive activated T lymphocyte immunotherapy for advanced lung cancer: results of a multicenter historical cohort study. Cancer Immunol Immunother 2012.
47. Zhou JH, Kang N, Cui LX, et al. Selection of culture media for the mass production of gammadelta T cells used in adoptive immunotherapy. Zhongguo Yi Xue Ke Xue Yuan Xue Bao 2011;33:644-648.
48. Zhou J, Kang N, Cui L, et al. Anti-gammadelta TCR antibodyexpanded gammadelta T cells: a better choice for the adoptive immunotherapy of lymphoid malignancies. Cell Mol Immunol 2012;9:34-44.
49. KondoM, SakutaK,NoguchiA, et al. Zoledronate facilitates largescale ex vivo expansion of functional gammadelta T cells from cancer patients for use in adoptive immunotherapy. Cytotherapy 2008;10:842-856.
50. Kang N, Zhou J, Zhang T, et al. Adoptive immunotherapy of lung cancer with immobilized anti-TCR gammadelta antibodyexpanded human gammadelta T-cells in peripheral blood. Cancer Biol Ther 2009;8:1540-1549.
51. Dokouhaki P, Han M, Joe B, et al. Adoptive immunotherapy of cancer using ex vivo expanded human gammadelta T cells: a new approach. Cancer Lett 2010;297:126-136.
52. Sakamoto M, Nakajima J, Murakawa T, et al. Adoptive immunotherapy for advanced non-small cell lung cancer using zoledronate-expanded gammadeltaTcells: a phase I clinical study. J Immunother 2011;34:202-211.
53. Hanagiri T, Shigematsu Y, Kuroda K, et al. Anti-tumor activity of human gammadelta T cells transducted with CD8 and with T cell receptors of tumor-specific cytotoxic T lymphocytes. Cancer Sci 2012.
54. Nakajima J,Murakawa T, Fukami T, et al. A phase I study of adoptive immunotherapy for recurrent non-small-cell lung cancer patients with autologous gammadelta T cells. Eur J Cardiothorac Surg 2010;37:1191-1197.
55. Zhong R, Teng J, Han B, et al. Dendritic cells combining with cytokine-induced killer cells synergize chemotherapy in patients with late-stage non-small cell lung cancer. Cancer Immunol Immunother 2011;60:1497-1502.
56. Yang L, Ren B, Li H, et al. Enhanced antitumor effects of DCactivated CIKs to chemotherapy treatment in a single cohort of advanced non-small-cell lung cancer patients. Cancer Immunol Immunother 2012.
57. Shi SB,Ma TH, Li CH, et al. Effect of maintenance therapy with dendritic cells: cytokine-induced killer cells in patients with advanced non-small cell lung cancer. Tumori 2012;98:314-319.
58. Kimura H, Iizasa T, Ishikawa A, et al. Prospective phase II study of post-surgical adjuvant chemo-immunotherapy using autologous dendritic cells and activated killer cells from tissue culture of tumor-draining lymph nodes in primary lung cancer patients. Anticancer Res 2008;28:1229-1238.
59. Motohashi S, Nagato K, Kunii N, et al. A phase I-II study of alpha-galactosylceramide-pulsed IL-2/GM-CSF-cultured peripheral blood mononuclear cells in patients with advanced and recurrent non-small cell lung cancer. J Immunol 2009;182:2492-2501.
60. Iliopoulou EG, Kountourakis P, Karamouzis MV, et al. A phase I trial of adoptive transfer of allogeneic natural killer cells in patients with advanced non-small cell lung cancer. Cancer Immunol Immunother 2010;59:1781-1789.
61. Ratto GB, Costa R, Maineri P, et al. Neo-adjuvant chemo/immunotherapy in the treatment of stage III (N2) non-small cell lung cancer: a phase I/II pilot study. Int J Immunopathol Pharmacol 2011;24:1005-1016.
62. Sun Z, Shi L, Zhang H, et al. Immune modulation and safety profile of adoptive immunotherapy using expanded autologous activated lymphocytes against advanced cancer. Clin Immunol 2011;138:23-32.
63. Siebert JC, Walker EB. Monitoring cytokine profiles during immunotherapy. Immunotherapy 2010;2:799-816.
64. Bonanno G, Iudicone P, Mariotti A, et al. Thymoglobulin, interferon-gamma and interleukin-2 efficiently expand cytokineinduced killer (CIK) cells in clinical-grade cultures. J Transl Med 2010;8:129.
65. Johansson A, Hamzah J, Payne CJ, et al. Tumor-targeted TNFalpha stabilizes tumor vessels and enhances active immunotherapy. Proc Natl Acad Sci USA 2012;109:7841-7846.
66. Ridolfi L, Bertetto O, SantoA, et al.Chemotherapy with or without low-dose interleukin-2 in advanced non-small cell lung cancer: results from a phase III randomized multicentric trial. Int J Oncol 2011;39:1011-1017.
67. Lefebvre JS, Maue AC, Eaton SM, et al. The aged microenvironment contributes to the age-related functional defects of CD4 T cells in mice. Aging Cell 2012.
68. Joseph RW, Peddareddigari VR, Liu P, et al. Impact of clinical and pathologic features on tumor-infiltrating lymphocyte expansion from surgically excised melanoma metastases for adoptive T-cell therapy. Clin Cancer Res 2011;17:4882- 4891.
69. Albright JW, BreamJH, Bere EW, et al. Aging of innate immunity: functional comparisons of NK/LAK cells obtained from bulk cultures of young and agedmouse spleen cells in high concentrations of interleukin-2. Exp Gerontol 2004;39:73-82.
70. Vakkila J, Lotze MT. Inflammation and necrosis promote tumour growth. Nat Rev Immunol 2004;4:641-648.
71. Kato M, Goto S, Soma G. Lymphokine-activated killer cell therapy combined with high-dose glucocorticoid showed clinical efficacy towards advanced lung carcinoma. Anticancer Res 2010;30:3125-3128.
72. Lu T, Ramakrishnan R, Altiok S, et al. Tumor-infiltrating myeloid cells induce tumor cell resistance to cytotoxic T cells in mice. J Clin Invest 2011;121:4015-4029.
73. Leen AM, Rooney CM, Foster AE. Improving T cell therapy for cancer. Annu Rev Immunol 2007;25:243-265.
74. Yao X, Ahmadzadeh M, Lu YC, et al. Levels of peripheral CD4 + FoxP3 + regulatory T cells are negatively associated with clinical response to adoptive immunotherapy of human cancer. Blood 2012.
75. Nagaraj S, Schrum AG, Cho HI, et al. Mechanism of T cell tolerance induced by myeloid-derived suppressor cells. J Immunol 2010;184:3106-3116.
76. Salagianni M, Lekka E,MoustakiA, et al.NKcell adoptive transfer combined with Ontak-mediated regulatory T cell elimination induces effective adaptive antitumor immune responses. J Immunol 2011;186:3327-3335.
77. Kodumudi KN,Weber A, Sarnaik AA, et al. Blockade of myeloidderived suppressor cells after induction of lymphopenia improves adoptive T cell therapy in a murine model of melanoma. J Immunol 2012;189:5147-5154.
78. Peng S, Lyford-Pike S, Akpeng B, et al. Low-dose cyclophosphamide administered as daily or single dose enhances the antitumor effects of a therapeutic HPV vaccine. Cancer Immunol Immunother 2013;62:171-182.
79. Son CH, Shin DY, Kim SD, et al. Improvement of antitumor effect of intratumoral injection of immature dendritic cells into irradiated tumor by cyclophosphamide in mouse colon cancer model. J Immunother 2012;35:607-614.
80. Pan PY, Ma G, Weber KJ, et al. Immune stimulatory receptor CD40 is required for T-cell suppression and T regulatory cell activation mediated by myeloid-derived suppressor cells in cancer. Cancer Res 2010;70:99-108.
81. Thanendrarajan S, Nowak M, Abken H, et al. Combining cytokine-induced killer cells with vaccination in cancer immunotherapy: more than one plus one? Leuk Res 2011;35:1136-1142.
82. Wang QJ, Wang H, Pan K, et al. Comparative study on antitumor immune response of autologous cytokine-induced killer (CIK) cells, dendritic cells-CIK (DC-CIK), and semi-allogeneic DC-CIK. Chin J Cancer 2010;29:641-648.
83. Valteau-Couanet D, Leboulaire C, Maincent K, et al. Dendritic cells for NK/LAK activation: rationale for multicellular immunotherapy in neuroblastoma patients. Blood 2002;100:2554-2561.
84. WestEJ, ScottKJ, JenningsVA, et al. Immune activationby combination human lymphokine-activated killer and dendritic cell therapy. Br J Cancer 2011;105:787-795.
85. Li Q, Lao X, Pan Q, et al. Adoptive transfer of tumor reactive B cells confers host T-cell immunity and tumor regression. Clin Cancer Res 2011;17:4987-4995.
86. Li Q, Teitz-Tennenbaum S, Donald EJ, et al. In vivo sensitized and in vitro activated B cellsmediate tumor regression in cancer adoptive immunotherapy. J Immunol 2009;183:3195-3203.
87. Huang X, Chen YT, Song HZ, et al. Cisplatin pretreatment enhances anti-tumor activity of cytokine-induced killer cells.World J Gastroenterol 2011;17:3002-3011.
88. Chen J, Huang X, Huang G, et al. Preconditioning chemotherapy with cisplatin enhances the antitumor activity of cytokineinduced killer cells in a murine melanoma model. Cancer Biother Radiopharm 2012;27:210-220.
89. Teitz-Tennenbaum S, Li Q, Davis MA, et al. Radiotherapy combined with intratumoral dendritic cell vaccination enhances the therapeutic efficacy of adoptive T-cell transfer. J Immunother 2009;32:602-612.
90. Thanendrarajan S, Kim Y, Schmidt-Wolf I. New adoptive immunotherapy strategies for solid tumours with CIK cells. Expert Opin Biol Ther 2012;12:565-572.
91. Li XD, Xu B, Wu J, et al. Review of Chinese clinical trials on CIK cell treatment for malignancies. Clin Transl Oncol 2012;14:102-108.
92. Di Stasi A, Tey SK, Dotti G, et al. Inducible apoptosis as a safety switch for adoptive cell therapy. N Engl J Med 2011;365:1673-1683.
93. Petersen RP, Campa MJ, Sperlazza J, et al. Tumor infiltrating Foxp3+ regulatory T-cells are associated with recurrence in pathologic stage I NSCLC patients. Cancer 2006;107:2866- 2872.
94. LiuH, Zhang T, Ye J, et al. Tumor-infiltrating lymphocytes predict response to chemotherapy in patients with advance non-small cell lung cancer. Cancer Immunol Immunother 2012.
95. Ito N, Suzuki Y, Taniguchi Y, et al. Prognostic significance of T helper 1 and 2 and T cytotoxic 1 and 2 cells in patients with non-small cell lung cancer. Anticancer Res 2005;25:2027- 2031.
96. Kuo CH, Lo CY, Chung FT, et al. Concomitant active tuberculosis prolongs survival in non-small cell lung cancer: a study in a tuberculosis-endemic country. PLoS One 2012;7:e33226.
97. RamalingamSS,Owonikoko TK,Khuri FR. Lung cancer: newbiological insights and recent therapeutic advances. CA Cancer J Clin 2011;61:91-112.
98. Fox BA, Schendel DJ, Butterfield LH, et al. Defining the critical hurdles in cancer immunotherapy. J Transl Med 2011;9:214.